Insider Ilan Ganot plans 7,205-share Solid Biosciences (SLDB) stock sale

Rhea-AI Filing Summary

Solid Biosciences insider Ilan Ganot has filed a Form 144 to sell common stock. The notice covers an intended sale of 7,205 shares of Solid Biosciences common stock through E*TRADE Financial Corporation on or about February 4, 2026, with an aggregate market value of $46,411.95. These shares were acquired the same day via settlement of vested restricted stock units, held indirectly through his wife, as compensation from the issuer. Over the prior three months, Ganot reported additional sales of 3,278, 1,053 and 191 shares of common stock, generating gross proceeds of $13,505.36, $5,717.79 and $1,258.69, respectively.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	7205	46411.95	82569192	02/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/04/2026	Settlement of vested restricted stock units indirectly held by the reporting person by his wife, Ms. Ganot	Issuer			7205	02/04/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ganot Ilan C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue CHARLESTOWN MA 02129	Common Stock	11/10/2025	3278	13505.36
Ganot Ilan C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue CHARLESTOWN MA 02129	Common Stock	01/05/2026	1053	5717.79
Ganot Ilan C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue CHARLESTOWN MA 02129	Common Stock	01/28/2026	191	1258.69

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the SLDB Form 144 filed by Ilan Ganot disclose?

The Form 144 for Solid Biosciences (SLDB) discloses that insider Ilan Ganot plans to sell 7,205 shares of common stock. The filing outlines the planned sale details, how the shares were acquired, and prior stock sales over the past three months.

How many Solid Biosciences shares is Ilan Ganot planning to sell?

The filing shows a planned sale of 7,205 shares of Solid Biosciences common stock. The shares are to be sold through E*TRADE Financial Corporation, with an indicated aggregate market value of $46,411.95 as of the filing details.

When were the SLDB shares to be sold by Ilan Ganot acquired?

The 7,205 Solid Biosciences shares were acquired on February 4, 2026 via settlement of vested restricted stock units. The filing notes these RSUs were held indirectly through Ganot’s wife and were received as compensation from the issuer.

What prior sales of Solid Biosciences stock has Ilan Ganot reported?

Over the past three months, Ilan Ganot reported selling 3,278, 1,053, and 191 shares of Solid Biosciences common stock. These transactions generated gross proceeds of $13,505.36, $5,717.79, and $1,258.69, respectively, according to the notice.

Through which broker will the SLDB insider sale be executed?

The planned sale of 7,205 Solid Biosciences shares is listed with ETRADE Financial Corporation as the broker. The broker’s address is provided as 3 Edison Drive, Alpharetta, GA 30005, and the shares are to be sold on the NASDAQ exchange.

On what date is the planned SLDB stock sale expected to occur?

The Form 144 indicates an approximate sale date of February 4, 2026 for the 7,205 Solid Biosciences common shares. This date matches both the acquisition date of the vested restricted stock units and the planned timing of the sale.